Matt Hoffman

The biotech company announced a collaboration with NS Pharma around CAP-1002’s commercialization and distribution ahead of its HOPE-3 phase 3 trial in Duchenne muscular dystrophy.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

After a prior phase 2 failure in CHANGE-MS showed signs of promise for progressive disease, the final patient visit has been completed in a trial of temelimab in relapsing disease, with results expected before the end of March 2022.

After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Bridget A. Bagert, MD, MPH. [LISTEN TIME: 32 minutes]

The senior VP of clinical research and deputy chief clinical officer of the neurology business group at Eisai spoke to the recent first enrollment in the Tau NexGen study of the investigational antimicrotubule binding region tau antibody, E2814.

After a post hoc analysis revealed promising results in a subgroup of younger adults with less disease burden, Ionis has announced that Roche will develop a new phase 2 trial.

Following the publication of data suggesting that EBV is a leading cause of MS, the director of the Ochsner MS Center and an investigator in an EBV-specific therapy clinical trial offered her reaction to the data.

Becky Tilahun, PhD, a clinical psychologist at Cleveland Clinic, offered insight into a recent study she and colleagues conducted exploring CBT-informed psychotherapy for patients with psychogenic nonepileptic seizures

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne-Maree Kelly, MD, MClinEd, FACEM. [LISTEN TIME: 23 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The Centers for Medicare and Medicaid Services issued a proposed decision memo detailing the coverage criteria for patients with Alzheimer disease to be covered by the federal health insurance platform when administered aducanumab (Aduhelm; Biogen).

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Roth, PhD. [LISTEN TIME: 12 minutes]

The safety profile in the low-dose cohort (6 x 1012 vg) is supportive of continued enrollment for a higher-dose cohort of 6 x 1013 vg. Additional data are anticipated to be announced in the second quarter of 2022.

Christina Szperka, MD, MSCE, the director of the Pediatric Headache Program at CHOP, offered her perspective on the challenges in conducting pediatric migraine trials and the advances made recently.

Amid a changing and evolving landscape for adult migraine care, Christina Szperka, MD, MSCE, director of the CHOP Pediatric Headache Program, offered insight into the standard experience in pediatric migraine care.

Christina Szperka, MD, MSCE, director of the CHOP Pediatric Headache Program, shared her perspective on the state of care and awareness for pediatric migraine amid the shifting landscape for adults.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

These news stories were the top conversations in the field and were often included in NeurologyLive®'s coverage in movement disorders such as Parkinson disease, Huntington disease, and essential tremor, among others.

Howard Fillit, MD, founding executive director, ADDF, provided his perspective on the state of the Alzheimer disease field as 2021 comes to a close.

George Vradenburg, JD, the chair and cofounder of UsAgainstAlzheimer’s; and Ian N. Kremer, JD, executive director, Leaders Engaged on Alzheimer's Disease, offer their insight into the downstream effects of the new pricing of Biogen’s aducanumab (Aduhelm).

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

After months of concern raised by the Alzheimer disease community about the list price for aducanumab (Aduhelm) of $56,000 yearly, Biogen has announced that the maintenance dose cost will be reduced to $28,200.

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Anton Porsteinsson, MD.

The post-marketing study of aducanumab (Aduhelm) is expected to enroll 1300 patients with early Alzheimer, with the final protocol to be submitted to the FDA in March 2022, and plans to initiate patient screening in May 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Szperka, MD, MSCE.